Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABSW), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics Inc (SABSW) is a clinical-stage biopharmaceutical leader advancing targeted human antibody therapies through its proprietary DiversitAb platform. This page provides investors and researchers with essential updates on clinical developments, financial disclosures, and strategic partnerships.
Access real-time announcements about therapeutic candidates like SAB-142 for type 1 diabetes, manufacturing innovations using transchromosomic cattle, and collaborative research milestones. Our curated news collection ensures you never miss critical updates on regulatory progress or pipeline expansions.
Key content includes earnings reports, trial result announcements, partnership disclosures, and analysis of competitive positioning in immunotherapy markets. All materials are sourced from verified channels to maintain factual accuracy and compliance standards.
Bookmark this page for streamlined access to SAB Biotherapeutics' latest advancements in developing fully human antibodies for autoimmune disorders and infectious diseases. Check regularly for authoritative updates directly impacting the company's trajectory in biopharmaceutical innovation.
SAB BIO (Nasdaq: SABS) announced two board appointments effective January 7, 2026: David Zaccardelli, Pharm.D. as Chair of the Board and Rita Jain, M.D. as an independent director.
Management highlights Zaccardelli's 20+ years of biopharma leadership and his role in the successful launch of Ohtuvayre, and describes Jain's two decades of experience in autoimmune and inflammatory disease drug development. Both appointees are presented as bringing complementary expertise to support clinical execution and advancement of SAB-142, the company's fully human anti-thymocyte immunoglobulin candidate for type 1 diabetes and other autoimmune diseases.
SAB Biotherapeutics (Nasdaq: SABS) announced that CEO Samuel J. Reich will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 7:30 a.m. PT / 10:30 a.m. ET in San Francisco.
A live webcast will be available in the Investors section of the company website at www.sab.bio, and an archived replay will be posted for approximately 30 days after the presentation.
SAB BIO (Nasdaq: SABS) announced the first patient was dosed with SAB-142 in the Phase 2b registrational SAFEGUARD trial on Dec 18, 2025. The trial targets stage 3 type 1 diabetes using a fully human anti-thymocyte immunoglobulin intended as a disease-modifying therapy. Enrollment is ongoing at multiple global sites, including the U.S., Australia, and New Zealand, with European sites joining soon. The company plans to share Phase 2b data in 2H 2027.
SAB BIO (Nasdaq: SABS) announced positive confirmatory Phase 1 results for SAB-142, an hATG candidate for stage 3 type 1 diabetes (T1D). In 68 treated participants (healthy volunteers and T1D patients), SAB-142 showed 0% serum sickness (0/68), 0% anti-drug antibody events (0/68), no drug-related serious adverse events, and transient lymphopenia that resolved to baseline within 1–3 days in 100% of subjects (68/68). Most adverse events were mild and infusion-related. A registrational Phase 2b SAFEGUARD trial is underway and recruiting globally, with the company on track to dose the first patient by year-end.
SAB BIO (Nasdaq: SABS) will present clinical data on SAB-142 at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia), December 9-11, 2025 in Singapore. Presentations on December 10, 2025 highlight Phase 1 results reporting a multi-specific mechanism of action, immunomodulation without sustained lymphodepletion, and a favorable safety profile without serum sickness or anti-drug antibodies at the target dose.
The company said it is currently in Phase 2b development for delaying progression of new-onset Stage 3 type 1 diabetes and expects to report additional Phase 1 data and dose the first Phase 2b SAFEGUARD patient later in 2025. Presentations will be posted on the company website.
SAB BIO (Nasdaq: SABS) initiated its registrational Phase 2b SAFEGUARD trial of lead candidate SAB-142 in new-onset Stage 3 T1D, activated multiple sites in the US, Australia and New Zealand, and is on-track to dose the first patient by year-end 2025. The company reported a strong cash position of $161.5 million at Sept 30, 2025 (vs. $20.8 million at Dec 31, 2024) and said its runway extends through 2028. Phase 1 data presented at EASD and ISPAD showed a favorable safety profile, no serum sickness or anti-drug antibodies at the target dose, and sustained immunomodulation. Financials: Q3 R&D $9.0M, other income $58.1M, and Q3 net income $45.4M. Company expects SAFEGUARD data in 2H 2027 and to present additional Phase 1 redosing data by year-end 2025.
SAb Biotherapeutics (Nasdaq: SABS) will present clinical and translational data for its lead program SAB-142 at the 51st ISPAD Annual Conference in Montréal, Nov 5–8, 2025.
Six presentations (four oral, two posters) describe Phase 1 results showing a multi-specific mechanism of action with sustained immunomodulation, a favorable safety profile at target dose without serum sickness or anti-drug antibodies, and a novel pharmacokinetic assay for measuring SAB-142.
The presentations cover specimen quality methods, binding specificity profiling, immunomodulation without sustained lymphodepletion, mechanism of action, PK assay details, and safety findings, led by SAB BIO scientific and clinical leaders.
SAb Biotherapeutics (Nasdaq: SABS) announced that members of management will participate in three investor conferences in November–December 2025: a UBS Global Healthcare Conference fireside chat on Nov 10, 2025 at 2:45 p.m. ET in West Palm Beach, a Guggenheim Healthcare Innovation Conference fireside chat on Nov 12, 2025 at 10:00 a.m. ET in Boston, and an Evercore Healthcare Conference fireside chat on Dec 2, 2025 at 3:50 p.m. ET in Coral Gables.
Live webcasts and archived recordings will be available on the company Investor Relations Events page at www.sab.bio.
SAB Biotherapeutics (NASDAQ: SABS) presented multiple studies at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), highlighting data for their novel SAB-142 treatment for type 1 diabetes (T1D).
The presentations featured results from their Phase 1 clinical study of SAB-142, a fully human anti-thymocyte immunoglobulin (ATG), which demonstrated sustained immunomodulation without causing prolonged lymphodepletion. The company also shared data about SAB-142's pharmacokinetic profile and discussed the INNODIA-sponsored MELD-ATG study, which validated the disease-modifying potential of ATG therapy in T1D patients.
SAB BIO is currently initiating its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, collaborating with INNODIA and leading European T1D centers.
SAB Biotherapeutics (Nasdaq: SABS) announced its participation at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, from September 15-19, 2025. The company will deliver five presentations focused on SAB-142, their novel immunotherapy treatment for type 1 diabetes.
The presentations include an INNODIA-hosted symposium and four oral presentations covering various aspects of SAB-142, including its immunomodulation properties, mechanism of action, pharmacokinetic assays, and specimen quality analysis for clinical trials. Key speakers include Dr. Alexandra Kropotova, EVP and Chief Medical Officer, Dr. Christoph Bausch, EVP and Chief Operating Officer, and Dr. Eric Sandhurst, Director of Program Management.
FAQ
What is the current stock price of SAB BIOTHERAPEUTICS (SABSW)?
